Table 2.
Prognostic capabilities of individual and combined biomarkers.
| Biomarker | # mishandled samples predicteda (sample processing delay time) |
Clinicalb | ||||
|---|---|---|---|---|---|---|
| <1 h | 1 h | 2 h | 4 h | >20 h | ||
| 5-Oxoproline | 0/38 | 0/5 | 3/5 | 4/5 | 45/45 | 15/141 |
| Lactate | 3/38 | 1/5 | 3/5 | 5/5 | 45/45 | 27/141 |
| Pyruvate | 20/38 | 3/5 | 4/5 | 4/5 | 45/45 | 54/141 |
| Fumarate | 5/38 | 2/5 | 2/5 | 2/5 | 45/45 | 24/141 |
| (I) 3 of 4 metabolitesc | 1/38 | 1/5 | 3/5 | 5/5 | 45/45 | 11/141 |
| (II) ornithine/arginine | 3/38 | 1/5 | 2/5 | 5/5 | 45/45 | 30/141 |
| Two-step prediction (both I and II) | 0/38 | 0/5 | 1/5 | 5/5 | 45/45 | 4/141 |
a
A threshold of a log2 (medscale) increase of 0.5 (1.41 on a linear scale) was used to predict mishandled samples using the listed biomarkers. Values are presented with the number of samples meeting these criteria over the total number of samples at each time-point.
b
Samples collected in a multicenter clinical setting. Actual processing time is unknown.
c
Increases meeting criteria for at least 3 of the 4 biomarkers (5-oxoproline, lactate, pyruvate, fumarate).